Logo image of SXTC

CHINA SXT PHARMACEUTICALS IN (SXTC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SXTC - VGG2161P1577 - Common Stock

1.8753 USD
+0.19 (+10.96%)
Last: 1/7/2026, 11:30:37 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SXTC. SXTC was compared to 191 industry peers in the Pharmaceuticals industry. SXTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SXTC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SXTC had negative earnings in the past year.
SXTC had a negative operating cash flow in the past year.
In the past 5 years SXTC always reported negative net income.
In the past 5 years SXTC reported 4 times negative operating cash flow.
SXTC Yearly Net Income VS EBIT VS OCF VS FCFSXTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of SXTC (-15.25%) is better than 61.78% of its industry peers.
SXTC has a better Return On Equity (-21.40%) than 65.97% of its industry peers.
Industry RankSector Rank
ROA -15.25%
ROE -21.4%
ROIC N/A
ROA(3y)-16.24%
ROA(5y)-14.76%
ROE(3y)-28%
ROE(5y)-27.24%
ROIC(3y)N/A
ROIC(5y)N/A
SXTC Yearly ROA, ROE, ROICSXTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

1.3 Margins

SXTC's Gross Margin of 21.11% is in line compared to the rest of the industry. SXTC outperforms 53.93% of its industry peers.
SXTC's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SXTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-16.61%
SXTC Yearly Profit, Operating, Gross MarginsSXTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

SXTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SXTC has been increased compared to 1 year ago.
The number of shares outstanding for SXTC has been increased compared to 5 years ago.
The debt/assets ratio for SXTC has been reduced compared to a year ago.
SXTC Yearly Shares OutstandingSXTC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
SXTC Yearly Total Debt VS Total AssetsSXTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

An Altman-Z score of 17.61 indicates that SXTC is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 17.61, SXTC belongs to the best of the industry, outperforming 86.91% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that SXTC is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.05, SXTC is in line with its industry, outperforming 52.36% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 17.61
ROIC/WACCN/A
WACC8.15%
SXTC Yearly LT Debt VS Equity VS FCFSXTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M 10M 15M

2.3 Liquidity

A Current Ratio of 3.54 indicates that SXTC has no problem at all paying its short term obligations.
The Current ratio of SXTC (3.54) is comparable to the rest of the industry.
SXTC has a Quick Ratio of 3.40. This indicates that SXTC is financially healthy and has no problem in meeting its short term obligations.
SXTC has a Quick ratio (3.40) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.54
Quick Ratio 3.4
SXTC Yearly Current Assets VS Current LiabilitesSXTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

SXTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.31%, which is quite impressive.
The Revenue has decreased by -9.73% in the past year.
Measured over the past years, SXTC shows a very negative growth in Revenue. The Revenue has been decreasing by -19.53% on average per year.
EPS 1Y (TTM)97.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.39%
Revenue 1Y (TTM)-9.73%
Revenue growth 3Y-12.51%
Revenue growth 5Y-19.53%
Sales Q2Q%-7.84%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SXTC Yearly Revenue VS EstimatesSXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SXTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTC Price Earnings VS Forward Price EarningsSXTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTC Per share dataSXTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SXTC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CHINA SXT PHARMACEUTICALS IN

NASDAQ:SXTC (1/7/2026, 11:30:37 AM)

1.8753

+0.19 (+10.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-31 2025-07-31
Earnings (Next)N/A N/A
Inst Owners0.27%
Inst Owner Change136.35%
Ins Owners35.32%
Ins Owner ChangeN/A
Market Cap217.59M
Revenue(TTM)1.74M
Net Income(TTM)-3.30M
Analysts0
Price TargetN/A
Short Float %0.2%
Short Ratio0.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 124.99
P/FCF N/A
P/OCF N/A
P/B 14.09
P/tB 14.1
EV/EBITDA N/A
EPS(TTM)-3.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.02
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.25%
ROE -21.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.11%
FCFM N/A
ROA(3y)-16.24%
ROA(5y)-14.76%
ROE(3y)-28%
ROE(5y)-27.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-16.61%
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.43%
Cap/Sales 0.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.54
Quick Ratio 3.4
Altman-Z 17.61
F-Score3
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)11.31%
Cap/Depr(5y)15.68%
Cap/Sales(3y)1.35%
Cap/Sales(5y)1.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.39%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-9.73%
Revenue growth 3Y-12.51%
Revenue growth 5Y-19.53%
Sales Q2Q%-7.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.64%
OCF growth 3YN/A
OCF growth 5YN/A

CHINA SXT PHARMACEUTICALS IN / SXTC FAQ

What is the ChartMill fundamental rating of CHINA SXT PHARMACEUTICALS IN (SXTC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SXTC.


What is the valuation status for SXTC stock?

ChartMill assigns a valuation rating of 0 / 10 to CHINA SXT PHARMACEUTICALS IN (SXTC). This can be considered as Overvalued.


What is the profitability of SXTC stock?

CHINA SXT PHARMACEUTICALS IN (SXTC) has a profitability rating of 1 / 10.